Time filter

Source Type

Amsterdam-Zuidoost, Netherlands

de Kort W.,Sanquin Blood Supply Foundation
Transfusion | Year: 2014

The cost-effectiveness of the donor health questionnaire (DHQ) as a tool to assess donor eligibility has not been quantified. This study focused on cost-effectiveness of the DHQ in preventing transfusion-transmitted infections (TTIs). Data on whole blood donor eligibility assessments in the Netherlands in 2008 to 2010 were analyzed. Based on test results and epidemiologic data on TTIs, the number of donor visits in their window phase was calculated. Subsequently, the incremental cost-effectiveness ratio (ICER) of the DHQ was calculated. The overall annual deferral rate in the study period was 9.6% (9.3%-10.0%). The annual deferral rate for TTI risk was 0.86% (0.82%-0.89%). Taking into account the number of self-deferrals, deferral rate for TTI risk in all donors was 1.90% (1.81%-2.02%). The calculated annual numbers of prevented cases of TTI were hepatitis B, 0.142; hepatitis C, 0.010; human immunodeficiency virus, 0.016; and syphilis, 0.135. The annual costs for TTI risk-related eligibility assessments, deferrals, and substitutions were €84,807 (€55,193-€123,811) for the blood establishment (BE) and €90,501 (€46,965-€159,571) for deferred donors. Annual savings were €991 (€276-€2325), while annual quality-adjusted life-years (QALYs) gained were 0.120 (0.059-0.226). Hence, the ICER for the DHQ on preventing TTIs was €696,744 (€315,422-€1,611,681) for BE costs only and €1,449,055 (€669,439-€3,145,961) including costs for deferred donors. The DHQ enhances self-selection and should not be abandoned. However, the DHQ is not a cost-effective tool for further reducing TTIs. The high costs per case prevented and the small number of QALYs gained argue against maintaining deferral policy through the DHQ at the current level. © 2013 American Association of Blood Banks. Source

Kitchen S.,Sheffield Haemophilia and Thrombosis Center | Gray E.,UK National Institute for Biological Standards and Control | Mertens K.,Sanquin Blood Supply Foundation
Haemophilia | Year: 2014

The dawning era of novel recombinant factor VIII and factor IX concentrates, many of which have been bioengineered to achieve prolonged activity, brings with it the need to consider the most appropriate clinical laboratory approaches for potency assignment, as well as the measurement of postinfusion levels. This session will highlight the known limitations and inconsistencies between existing assay methodologies with respect to currently available products, and discuss some of the early data with respect to the novel agents. © 2014 John Wiley & Sons Ltd. Source

Novo Nordisk AS and Sanquin Blood Supply Foundation | Date: 2015-09-23

The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.

Kramer K.,Sanquin Blood Supply Foundation | Kramer K.,Wageningen University | Verweij M.F.,Wageningen University | Zaaijer H.L.,Sanquin Blood Supply Foundation
Transfusion | Year: 2015

BACKGROUND The availability of costly safety measures against transfusion-transmissible infections forces Western countries to confront difficult ethical questions. How to decide about implementing such measures? When are such decisions justified? As a preliminary to addressing these questions, we assessed which concerns shape actual donor blood safety policymaking in five Western countries. STUDY DESIGN AND METHODS Our qualitative study involved determining which issues had been discussed in advisory committee meetings and capturing these issues in general categories. Appropriate documents were identified in collaboration with local decision-making experts in Canada, Germany, the Netherlands, The United States, and the United Kingdom. The introduction of hepatitis B virus nucleic acid testing and selected measures against variant Creutzfeldt-Jakob disease, West Nile virus, and Q-fever were chosen as cases representing decision-making on safety measures with high costs and low or uncertain added safety. RESULTS A broad inventory of concerns was established, including: 1) nine categories of advantages and disadvantages of candidate safety policies; 2) six kinds of difficulties in assessing risks and forecasting the effects of safety policies; 3) 13 decision-making principles; and 4) six kinds of practical barriers hampering the translation of candidate policies into decisions. CONCLUSION Blood safety policymaking involves a wide variety of competing concerns, and approaches to reconcile these considerations are themselves contested. Developing a systematic decision-making approach requires ethical reflection on, among others, reasonable costs of safety and the value of transparency in public policy. © 2015 AABB. Source

Prinsze F.J.,Sanquin Blood Supply Foundation | Zaaijer H.L.,Sanquin Blood Supply Foundation
Vox Sanguinis | Year: 2012

Background and Objectives Blood donor screening reduces the infectious hazards related to blood transfusion, but the range of agents to be screened for is debatable. In 1993, the screening of all blood donations for Human T-Cell Lymphotropic virus (HTLV) was introduced in the Netherlands. We analysed the outcome and costs of HTLV donor screening. Methods For the years 2001-2010, the number of HTLV infections among new and regular donors was used to estimate the prevented number of HTLV-infected donors in the donor pool and the amount of morbidity prevented among recipients. Results Human T-Cell Lymphotropic virus screening in the Netherlands detects per year on average 1·4 infected new donors and 0·5 infected regular donors. The prevalence among new donors is 30 times higher than the incidence among regular donors. Without HTLV screening, 14 HTLV-infected donors would be donating blood, causing 0·8 to 0·007 cases of HTLV disease per year. Conclusion The lack of accurate estimators for infectivity and pathogenicity hampers the estimation of morbidity and mortality that HTLV-infected transfusions would cause. Leucodepletion may be as effective as HTLV donor screening; its effect on HTLV transmission should be studied. © 2011 The Author(s). Vox Sanguinis © 2011 International Society of Blood Transfusion. Source

Discover hidden collaborations